NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Novavax, Inc. (NVAX) Stock Analysis

Novavax, Inc. (NVAX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NVAX

$10.22

−$0.12 (−1.16%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NVAX with… →

NVAX Key Statistics

As of Sep 4, 2026
Trading
Open
$10.50
Previous Close
$10.34
Day's Range
10.05–10.75
52-Week Range
6.20–11.97
Volume
5.12M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.45
Valuation
Market Cap
$1.69B
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.32
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.53
Financials (FY)
Revenue (FY)
$1.12B+64.69%
Net Income (FY)
$440.30M
Profit marginThe share of revenue left as profit after all costs and taxes.
−59.87%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
164.95M
1-Year Return
+31.19%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NVAX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+52.08%
2025−16.42%
2024+67.50%
2023−53.31%
2022−92.81%
2021+28.30%
2020+2701.76%
2019−89.18%
2018+48.39%
2017−1.59%
2016 (partial year)−83.24%

As of September 4, 2026.

NVAX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.12B$440.30M39.2%
2024$682.16M−$187.50M−27.5%
2023$556.38M−$545.06M−98.0%
2022$1.60B−$657.94M−41.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.12B$1.05B$550.64M$440.30M39.2%
2024$682.16M$479.42M−$248.93M−$187.50M−27.5%
2023$556.38M$212.61M−$566.51M−$545.06M−98.0%
2022$1.60B$696.31M−$644.74M−$657.94M−41.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NVAX Valuation vs Biotechnology Median

Median of 656 stocks
MetricNVAXBiotechnology medianvs median
P/S ratio4.0715.260.3x the median
Profit margin−59.87%0.00%59.9 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Novavax, Inc. (NVAX) is capitalised at $1.69B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 749.

The 52-week range on file runs from $6.20 to $11.97. NVAX last closed at $10.22 on September 4, 2026. That is −$0.12 (−1.16%) against the previous close. The latest close sits 64.84% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.12B. Against the prior fiscal year total of $682.16M, that is a change of +64.69%. The same year closed with net income of $440.30M. The reported profit margin is −59.87%. That is 59.9 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.53.

Across the 4 fiscal years on file, revenue moves from $1.60B in 2022 to $1.12B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.32. Measured against sales, the shares trade at 4.07 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +31.19%. Across 10 years the annualized return works out at −22.77%. Beta against the wider market is reported at 2.45. Daily returns over the trailing 10 years annualize to a volatility of 115.53%.

Growth & Income

No dividend is on file for NVAX.

2026 is still running; the price is +52.08% year to date. The strongest complete calendar year on file is 2020 at +2,701.76%; the weakest is 2022 at −92.81%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Novavax, Inc. (NVAX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Novavax, Inc. NVAX $1.69B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Novavax, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Visit website →